Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crotoxin

Next Previous
Drug Profile

Crotoxin

Alternative Names: CB24; Cytotoxic PLA2; NSC-624244

Latest Information Update: 31 Jul 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ventech
  • Developer Celtic Biotech; Celtic Biotech Iowa
  • Class Antineoplastics; Venoms
  • Mechanism of Action Apoptosis stimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer

Most Recent Events

  • 18 Jul 2017 Celtic Biotech re-initiates enrolment in a phase I trial in Cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in France (IV) (NCT01481532)
  • 10 Mar 2017 Phase-II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in France (IV)
  • 13 Feb 2015 Celtic Biotech suspends enrolment in a phase I trial in Cancer (Metastatic disease, Late-stage disease, Second-line therapy or greater) in France (IV) (NCT01481532)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top